Список проголосовавших за комментарий " Gapping up/down: LJPC +40.2% following positive data; GOGO +5% on earnings, TSLA -2.7% on Goldman downgrade<p><strong>Gapping up:</strong></p><p><strong>Earnings</strong>: <strong>GOGO</strong> +5.3%, <strong>LUK</strong> +3.0%.</p><p><strong>General news</strong>:</p><ul><li><strong>LJPC</strong> +40.2% (announces positive top-line results from athos-3 phase 3 study of LJPC-501; 'primary efficacy endpoint analysis highly statistically significant'),</li><li><strong>PIRS</strong> +17.2% (granted ASKA Pharma an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose Phase 2a study; co will receive an immediate option payment of $2.75 mln from ASKA),</li><li><strong>ATRS</strong> +12.0% (announces that the New Drug Application for QuickShot Testosterone has been accepted for standard review by the FDA),</li><li><strong>ACRX</strong> +8.3% (New Drug Application for DSUVIA accepted for filing; PDUFA date is October 12, 2017),</li><li><strong>FEYE</strong> +2.3% (still checking)</li></ul><p><strong>Analyst actions</strong>:</p><ul><li><strong>PTEN</strong> +3.4% (added to US 1 List at BofA/Merrill),</li></ul><p> </p><p><strong>Gapping Down:</strong></p><p><strong>Earnings related</strong>: <strong>BCRX</strong> -16.2%, <strong>SSTK</strong> -11.4%, <strong>JKS</strong> -2.2%</p><p><strong>General news</strong>:</p><ul><li><strong>NVFY</strong> -9.7% (pulling back following recent gains)</li><li><strong>DRYS</strong> -8.5% (still checking)</li><li><strong>SPKE</strong> -7.0% (pulling back following Friday's spike on M&A chatter)</li><li><strong>VIAV</strong> -2.8% (commences $400 mln private offering of its Senior Convertible Notes due 2024; intends to use up to $75 mln of the proceeds from the offering to repurchase common stock to its existing program)</li></ul><p><strong>Analyst actions:</strong></p><ul><li><strong>SUI</strong> -5.9% (downgraded to Neutral from Buy at Citigroup)</li><li><strong>URBN</strong> -3.3% (downgraded to Sell from Neutral at MKM Partners)</li><li><strong>TSLA</strong> -2.7% (downgraded to Sell from Neutral at Goldman; tgt lowered to $185 from $190)</li><li><strong>NVMI</strong> -2.7% (downgraded to Hold at Stifel; tgt $18)</li></ul>"